Key Takeaways
- A reset year, not a growth year: FY22 revenue fell 22% YoY to ₹1,289 Cr and EBITDA collapsed to ₹92 Cr from ₹400 Cr, driven by a failed R&D pipeline, an idle Vizag plant, and the called-off Aurore merger.
- The merger reversal is a strategic pivot: Aurore's COVID-dependent portfolio collapsed, making the original swap ratio untenable for Solara shareholders; management is now fully focused on an organic rebuild.
- Two large cost centers are bleeding: The Vizag SEZ plant incurred ₹58 Cr of fixed cost with zero revenue because no regulatory inspection happened, while R&D spend delivered zero new product revenue for the first time in Solara's history.
- Recovery hinges on regulatory unlocks: 10 new approvals are pending reclassification of Cuddalore's OAI status, and a Vizag inspection is needed to start sales; management bets both will happen in FY23.
- What to watch next quarter: Whether the OAI reclassification actually materializes in H1 FY23, any progress on Vizag inspection scheduling, and whether Ibuprofen demand recovery converts into validation-batch orders.
The Called-Off Merger & Leadership Reset
- Aurore's COVID bet soured: The merger was reversed because Aurore had an over-dependence on COVID products, and in the recent six months demand for its primary tactical products dropped significantly, making the economics no longer sensible for Solara shareholders to keep the ratios intact.
- Non-COVID ramp-up stalled: Aurore's new Hyderabad facility has not been inspected, delaying the larger ramp-up of non-COVID products; management estimates Aurore will take at least another year to year-and-a-half to bounce back, which would be a distraction for Solara's core business.
- Leadership returns to rebuild: Jitesh Devendra was appointed CEO/MD and Hariharan Subramaniam as CFO, both returning to Solara to reset the company; the stated priority is to rebuild confidence with stakeholders, customers, and employees.
- Arun Kumar exiting Aurore: Arun Kumar is in the process of exiting his interest in Aurore, a process of three to six months; his interest in the next six months will be fully committed and aligned only in Solara.
Arun Kumar: "Unfortunately, with an over dependence on COVID products in the case of Aurore and in the recent six months we have seen a lack of demand for the primary tactical products that Aurore was selling, dropping significantly where the economies does not make any more sense for the Solara shareholders to keep the ratios intact, and it would not be appropriate for us to then recommend to the Board that as promoters that the merger should go through."
The Idle Vizag Plant
- Zero revenue, full fixed cost: The Vizag SEZ plant earned no revenue in FY22 because no regulatory inspections happened last year; the plant must be kept ready for inspection at any time, incurring ₹58 Cr of fixed costs on utilities, salaries, HVAC maintenance, and QC equipment maintenance.
- Inspection is the unlock: The plant is an SEZ and must be qualified by customers and regulators before any product can be sold; management expects the Vizag site to be inspected during this fiscal year, considering audits have now commenced full swing.
- Partial customer prepayment: Part of the plant investment was prepaid by a customer for volumes, indicating some demand commitment exists but cannot be realized without inspection.
- Near-term goal is breakeven: The immediate priority is to get Vizag off the roads to achieve breakeven and profitable growth, including getting the facility triggered for inspection; plans exist for sales from H2 FY23 in markets without regulatory binding once minimal documentation is completed.
R&D Pipeline Failure & New Product Strategy
- Zero new product revenue: For the first time in Solara's history, the company was not successful in customer acquisition for new products; typically six or seven new products feed formulation customers and R&D costs are squared off through validation-batch sales.
- R&D spend under review: All R&D cost is routed through the P&L only, with no intangible assets held on the books; management is rationalizing the spend and does not expect more than a ₹54–55 Cr run rate going forward.
- Six filings planned for FY23: The company plans to file at least six new products in FY23, which will give some revenues in FY23 and FY24; new products usually cover the cost of R&D expenses via validation batch sales.
- Non-Ibu portfolio reviving: Last year was dull for products like Oseltamivir and Succinylcholine Chloride; demand is now coming back for Gabapentin, Sevelamer Carbonate, and Praziquantel, with market extensions done in the last three to four years now fructifying as approvals come in.
Arun Kumar: "This was the first time in the history of Solara that in the last 12 months, we were not successful on that front. So that is why the revenue from that activity has been shown as zero while the costs have been incurred."
Regulatory Overhang: Cuddalore OAI Status
- 10 approvals held hostage: Ten new approvals are pending reclassification of the Cuddalore OAI status; management firmly believes reclassification will happen within the first half of this financial year, based on data points provided to the US FDA now that inspections have been initiated.
- H2 revenue bet: New sales from Cuddalore have been considered in the second half of FY23, contingent on OAI reclassification in H1; this is a belief, not a guarantee.
- Ranitidine CEP restored: The CEP for Ranitidine was restored back in July 2021 based on evidence of work done, providing one positive regulatory data point.
Margin & Balance Sheet Pressure
- Gross margin collapse: FY22 gross margin fell to 47.6% from 54.7% in FY21, and Q4 gross margin was 44.1%, due to under-recoveries from the Vizag facility and delay in new product introduction.
- Two products under margin stress: Two key products are facing price reversion to normalcy and raw material price increases due to the current international situation, impacting gross margins; management expects this to normalize in H2 FY23.
- COVID inventory overhang: Net debt increased because of planned inventory buildup for COVID-related business; two COVID products are in inventory, one getting sold in Q1 and Q2 of FY23, the other with a customer-committed liquidation plan; no loss of inventory is expected and price realizations are not expected to be lower.
- Q4 production cut: Production level was very low in Q4, with opening stock getting sold and much less production activity occurring, causing a decrease in inventory; had production been normal, this inventory reduction would not have occurred, and the impact is expected to normalize in H2 FY23.
- Debt-to-EBITDA focus: The primary focus is to achieve a comfortable net debt to EBITDA run rate and improve cash flow by prudent application of capital.
Jitesh Devendra: "Our focus right now is to strengthen the foundation of Solara to get back to its historical run rates... the next focus is in terms of how we improve our EBITDA margins, our gross margins which has been traditionally at about 50% to 54%, we see that coming back in second half of this year."
Ibuprofen & Non-Ibu Business Dynamics
- Ibu demand returning: Last year was not a good year for Ibuprofen, but demands have started coming back from existing customers and inquiries from new customers are being received; management hopes to convert inquiries into new business opportunities by supplying validation batches in this financial year.
- Pricing pressure on Ibu: Pricing has been stable except for Ibuprofen where there has been a reduction; when raw material price increases are assessed as not temporary, the company discusses with customers and either passes on the cost or splits it 50:50.
- Raw material normalization expected: Management expects raw material prices to come to normal by Q2 FY23, once the international situation normalizes.
- Revenue split undisclosed: Management declined to give a revenue split between Ibu and non-Ibu business, stating they do not provide that breakdown.
- Regulated market shift: The bulk of Q4 business was directly to customers, with dependency on channel partners considerably reduced; traditionally 90–95% of regulated market business has been direct.
CRAMS & Long-Term Vision
- CRAMS organization being built: A dedicated business development team member for North America is being hired, adding to the existing one focused on Europe; this is part of building the CRAMS organization from a front-end perspective.
- Four growth pillars defined: The organic strategy rests on Ibu and non-Ibu APIs, continuous improvement programs including backward integration for key APIs, new product introductions, and CRAMS.
- Vision unchanged, timeline extended: Management remains confident of emerging amongst the top 10 global players but acknowledges the timing has shifted, probably taking two more years due to the circumstances in the business environment; the company will not shy away from inorganic transactions but cannot be distracted from the strategic goal of steadying the ship first.
- Five-year success definition: To be a preferred API supplier, a high-quality player with regulated markets as primary focus, having more portfolio, different chemistry capabilities, getting into new areas, and building a CRAMS business of scale; management declined to put a revenue number to this vision.
Arun Kumar: "I do not think the vision has moved maybe the timing has shifted... I am very, very confident that we will still emerge amongst the top 10 global players. We probably will take two more years but and that is to do with the circumstances in the business environment that we operate in."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| OAI reclassification | Cuddalore OAI status reclassified based on data provided to US FDA | H1 FY23 |
| New product filings | File at least six new products | FY23 |
| Vizag inspection | Vizag site inspected by regulators | FY23 |
| Gross margin recovery | Gross margins return to 50–54% range | H2 FY23 |
| Raw material cost normalization | Raw material prices normalize as international situation stabilizes | Q2 FY23 |
| Two-product margin pressure | Price reversion and RM price increase on two key products normalize | H2 FY23 |
| COVID inventory liquidation | Two COVID products in inventory sold down with no loss expected | Q1–Q2 FY23 |
| Arun Kumar Aurore exit | Full exit from Aurore interest, full commitment to Solara | 3–6 months |
| Organic capex | ₹100 Cr for ongoing Vizag investments and maintenance capex | FY23 |
| R&D spend cap | R&D spend rationalized to not more than ₹54–55 Cr run rate | Ongoing |
Key Metrics
| Metric | Q4 FY22 |
|---|---|
| Revenue | ₹367 cr, 90% of historical run rate |
| FY2022 revenue | ₹1,289 cr, compared to ₹1,645 cr in FY2021 |
| Gross margin | 44.1% in Q4; 47.6% for FY2022, compared to 54.7% in FY2021 |
| Adjusted EBITDA | ₹50 cr, 13.6% margin |
| FY2022 consolidated EBITDA | ₹92 cr, compared to ₹400 cr in FY2021 |
| Reported EBITDA margin (adjusted for inventory changes and Vizag) | 19.7% |
| Core business revenue | ₹367 cr in Q4; ₹1,288 cr for FY2022 |
| Core business EBITDA | ₹40 cr in Q4; ₹200 cr for FY2022 |
| R&D led growth business revenue | Zero in Q4 and FY2022 |
| R&D led growth business EBITDA | minus ₹54 cr for FY2022 |
| Vizag led business revenue | Zero in Q4 and FY2022 |
| Vizag led business EBITDA | minus ₹58 cr for FY2022 |
| Net debt increase | Over 50% |
| Credit rating | A- for long-term and working capital, retained |
| CRAMS revenue share | 7% to 8% of total revenues |
| Ibuprofen price | $11 to $12 per kilo average |
| New products revenue share | 5% of revenue, from products launched in prior year |
| FY2023 planned organic capex | ₹100 cr, including Vizag investments and maintenance capex |
| Ibuprofen annual demand sold in FY2022 | 40% |
| FY2023 new product filing target | At least six new products |
| Raw material cost increase | 30% to 40% for key materials; solvents up more than 40% |
| Historical gross margin range | 50% to 54% |